The current diagnosis of prostate cancer based on PSA values and systematic biopsy has limitations in its efficacy of detection and staging.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Technical advances on imaging over the last decade, mainly MRI, enable improvements in the strategy of prostate cancer management in diagnosis, staging, follow up and therapy monitoring. MRI enables the combination of morphological (T2 sequences) and, at the same time, functional information by means of the application of sequences such as spectroscopy (SMRI), diffusion and dynamic intravenous contrast (CMRI) in the same study, giving the multiparametric MRI (mpMRI). Currently, it is not necessary to apply all sequences to obtain an mpMR study of optimal efficacy, so that a time shorter than 30 minutes is enough to obtain the necessary information depending on the clinical indication. The main clinical indications of prostatic MRI are a) local, regional or distance staging; b) Detection or guide for diagnostic biopsy for clinical risk suspicion or negative result in previous biopsies; c) active surveillance; and d) therapeutic monitoring. Furthermore, one of the most relevant features of prostate cancer, and a challenge for the mpMRI techniques is to be able to differentiate aggressive and non-significant neoplasias (latent). This update tries to review the current role of mpMRI in the management of prostate cancer using in combination the anatomical (T2) and functional (SMRI, DMRI and CMRI) information. We also describe the European prostate mpMRI guidelines, PI-RADS (Prostate imaging reporting data System).
Vilanova JC, Luna-Alcalá A, Boada M, Barceló J. Are you the author?
Unidad de Resonancia Magnética, Clínica Girona, Girona, España; Servicio de Radiodiagnóstico, IDI, Institut de Diagnòstic per la Imatge, Institut Català de la Salut, Girona, España; Departamento de Ciencias Médicas, Facultad de Medicina, Universidad de Girona, Girona, España; Área de Imagen de Abdomen, RESSALTA, Hospitales San Juan de Dios y Cruz Roja, Grupo Health Time, Córdoba, España; Departamento de Radiología de Case, Western Reserve University, Cleveland, OH, USA.
Reference: Arch Esp Urol. 2015 Apr;68(3):316-33.
Article in Spanish.